Skip to main content

Rallybio Corp

RLYB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001739410

No open-market purchases or sales by Rallybio Corp insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $68.1M in total; Viking Global Investors is the only superinvestor holding it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −1 vs. previous quarter
37
13F valueReported value at the end of Q2 2026
$68.1M
Superinvestors holdingAt the end of Q2 2026
1

Price chart

Superinvestors holding RLYB, Q2 2026

1 superinvestor reports holding Rallybio Corp on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Viking Global Investors

Andreas Halvorsen

<0.1%

Rallybio Corp's share of the portfolio

Shares
524,347
Value
$8.39M

Latest insider trades

Open-market purchases and sales by Rallybio Corp insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 20, 2026 (view filing)8:45 PM ETMay 18-192 daysSchneeberger Daniel and 1 other10% OwnerPPurchase+16.2K$13.98+$226.6K+1.8%926.4K after3 lots
May 15, 2026 (view filing)8:49 PM ETMay 13-152 daysSchneeberger Daniel and 1 other10% OwnerPPurchase+79.6K$13.99+$1.11M+9.6%910.1K after4 lots
May 13, 2026 (view filing)9:22 PM ETMay 11-122 daysSchneeberger Daniel and 1 other10% OwnerPPurchase+50.8K$14.00+$711.1K+6.5%830.6K after4 lots
May 6, 2026 (view filing)9:32 PM ETMay 4-52 daysSchneeberger Daniel and 1 other10% OwnerPPurchase+155.9K$13.97+$2.18M+25.0%779.8K after3 lots
Feb 23, 2026 (view filing)Feb 23Same dayLieber Jonathan IChief Financial OfficerSSale−789$5.06−$3.99K−16.1%4.12K after
Mar 16, 2023 (view filing)Mar 142 daysLieber Jonathan ISee RemarksPPurchase+5.00K$5.21+$26.1KNew position5.00K after
Mar 9, 2023 (view filing)4:35 PM ETMar 72 daysRocklage Scott M and 3 others10% OwnerSSale−100.0K$8.20−$820.0K−4.0%2.38M afterDuplicate filing
Mar 9, 2023 (view filing)Mar 72 daysParmar KushDirectorSSale−100.0K$8.20−$820.0K−4.0%2.38M after
Nov 17, 2022 (view filing)4:30 PM ETNov 152 daysViking Global Investors LP and 7 others10% OwnerPPurchase+3.33M$6.00+$20.0M–3.33M afterDerivative
Jun 7, 2022 (view filing)5:02 PM ETJun 34 daysRocklage Scott M and 5 others10% OwnerSSale−150.0K$12.50−$1.88M−5.7%2.48M after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Rallybio Corp at the end of Q2 2026; share changes are against Q1 2026.

See all 37 holders
Institutions holding RLYB in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
ADAR1 Capital Management, LLC926,352$14.8M0.70%+905,817+4,411.1%Added
FMR LLC794,720$12.7M0.00%+1,269+0.2%Added
Viking Global Investors LPSuperinvestorViking Global Investors524,347$8.39M0.02%00.0%Unchanged
TPG GP A, LLC378,551$6.06M0.12%00.0%Unchanged
Nantahala Capital Management, LLC376,844$6.03M0.18%+76,209+25.3%Added
Pivotal bioVenture Partners Investment Advisor LLC300,579$4.81M1.56%00.0%Unchanged
Renaissance Technologies LLC199,907$3.20M0.00%+43,380+27.7%Added
Vanguard Capital Management LLC172,497$2.76M0.00%+60,457+54.0%Added
Almitas Capital LLC120,682$1.93M0.46%−70,524−36.9%Reduced
Rangeley Capital, LLC104,850$1.68M1.56%+74,720+248.0%Added